SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma
Authors
Keywords
-
Journal
BLOOD
Volume 139, Issue 8, Pages 1160-1176
Publisher
American Society of Hematology
Online
2022-02-25
DOI
10.1182/blood.2021012448
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
- (2020) Eric R. Fedyk et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
- (2020) Ilaria Saltarella et al. Cells
- Isatuximab: First Approval
- (2020) Sohita Dhillon DRUGS
- Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs
- (2020) Alicia M Chenoweth et al. IMMUNOLOGY AND CELL BIOLOGY
- A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
- (2020) Joseph Mikhael et al. LEUKEMIA
- Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
- (2020) Domenico Viola et al. LEUKEMIA
- Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
- (2020) Meletios A. Dimopoulos et al. LEUKEMIA
- Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
- (2020) Tineke Casneuf et al. LEUKEMIA
- MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
- (2020) Marc S Raab et al. Lancet Haematology
- Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
- (2020) Laurens E. Franssen et al. Journal of Clinical Medicine
- Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses
- (2020) Alak Manna et al. Blood Advances
- Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells
- (2020) Chen Zhu et al. Frontiers in Immunology
- Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
- (2019) Thomas Martin et al. Blood Cancer Journal
- Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
- (2019) Yahiya Y. Syed DRUGS
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
- (2019) Djordje Atanackovic et al. LEUKEMIA
- The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies
- (2019) Paul G. Richardson et al. BLOOD
- Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine
- (2019) Sietse Q. Nagelkerke et al. Frontiers in Immunology
- Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
- (2019) Thomas G. Martin et al. Cells
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma
- (2018) Niels W. C. J. van de Donk et al. BRITISH JOURNAL OF HAEMATOLOGY
- Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
- (2018) Marjorie Pick et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia
- (2018) Jyoti Naik et al. HAEMATOLOGICA
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- IgG Fc engineering to modulate antibody effector functions
- (2017) Xinhua Wang et al. Protein & Cell
- Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
- (2017) Antonella Chillemi et al. Frontiers in Immunology
- Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
- (2017) Gianfranco Pittari et al. Frontiers in Immunology
- Predictive Value of FcR Polymorphisms
- (2017) Riccardo Dolcetti JAMA Oncology
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Daratumumab: First Global Approval
- (2016) Kate McKeage DRUGS
- The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
- (2016) Marije B. Overdijk et al. JOURNAL OF IMMUNOLOGY
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunosurveillance and therapy of multiple myeloma are CD226 dependent
- (2015) Camille Guillerey et al. JOURNAL OF CLINICAL INVESTIGATION
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Anti-CD40 and Anti-IL-23 Monoclonal Antibody Therapy Effectively Suppresses Tumor Growth and Metastases
- (2014) B. von Scheidt et al. CANCER RESEARCH
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
- Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
- (2014) I. S. Nijhof et al. HAEMATOLOGICA
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
- (2013) James D Mellor et al. Journal of Hematology & Oncology
- Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
- (2012) M. Chesi et al. BLOOD
- Mouse model recapitulating human Fc receptor structural and functional diversity
- (2012) P. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses
- (2008) P. Bruhns et al. BLOOD
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies
- (2008) Marta Chesi et al. CANCER CELL
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started